CompaniesPrime Medicine

Prime Medicine

active

Cambridge, MA, United States

Founded 2021

About

Gene Editing Technology

Areas of Focus

Categories

Boston & New England

Team (14)

Allan ReineMDChief Executive Officer

Andrew AnzaloneMD

Andrew AnzaloneMD, PhDCo-founder

team_memberfounder

David LiuPhDCo-founder

team_memberfounder

David SchenkeinMD

David SchenkeinMDBoard Member

Jeff MarrazzoExecutive Chair

team_memberboard_chair

View all 14 team members →

Clinical Trials (1)

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

12

By Phase

PHASE1/PHASE2: 1

By Status

ACTIVE_NOT_RECRUITING: 1

Clinical Trials Pipeline1 trial

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2023

2024

2025

2026

2027

2028

2029

2030

2031

Today

Hover over trial bars to see details

Recent Trials

NCT06559176Lead Sponsor

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

PHASE1/PHASE2Active, not recruiting

12 participants

Started: Oct 17, 2024 · Completed: Feb 28, 2030

Funding History (20)

8-K

Sep 8, 2025

8-K

Aug 7, 2025

8-K

Aug 5, 2025

8-K

Jul 31, 2025

8-K

Jul 30, 2025

8-K

Jul 15, 2025

DEF 14A

Jul 14, 2025

8-K

Jun 5, 2025

DEFA14A

May 19, 2025

8-K

May 19, 2025

Locations (1)

Headquarters

Cambridge, MA, United States

Map

Loading map...